You are here

Receptor-Targeted Neuroendocrine Tumor Imaging with Generator-Produced Cu-62

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA206709-01A1
Agency Tracking Number: R43CA206709
Amount: $218,629.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA15-269
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-01
Award End Date (Contract End Date): 2019-02-28
Small Business Information
8022 EL RIO ST
Houston, TX 77054-4184
United States
DUNS: 806763793
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (713) 747-7324
Business Contact
Phone: (713) 397-2746
Research Institution

Project Summary
This Phase research project will develop a somatostatin receptor targeted Cu radiopharmaceutical
for clinical imaging of neuroendocrine tumors with positron emission tomography PET The short
lived Cu radiolabel is readily and repeatedly available for on demand radiopharmaceutical labeling
via a compact modular Zn Cu radionuclide generator system developed by Proportional
Technologies Inc Somatostatin receptors are found to be highly expressed by most neuroendocrine
tumors and are a well established molecular target for PET detection of these malignancies with a
family of Ga labeled receptor targeted peptides that have come into widespread clinical use outside
the USA This project will develop an alternative approach to PET imaging of neuroendocrine tumors
employing Cu DOTA TATE as a radiopharmaceutical that can readily be employed for assessment of
tumor burden while still allowing immediate independent F FDG PET assessment of tumor
aggressiveness thus more fully characterizing the individualandapos s disease state Cu DOTA TATE will also
be attractive for neuroendocrine tumor imaging in pediatrics due to relatively low patient radiation
exposure when imaging with such a short lived nuclide Our commercialization approach will be to seek
FDA approval for the combination of our Cu generator and a companion sterile kit that allows on
demand technologist compounding of the Cu DOTA TATE radiopharmaceutical immediately prior to
injection For this Phase project our Specific Aims are to produce and validate a lyophilized kit
formulation for on demand clinical site compounding of Cu DOTA TATE and to evaluate Cu
DOTA TATE distribution pharmacokinetics and dosimetry in humans Additionally the feasibility of
whole body Cu DOTA TATE tumor imaging will be documented by direct comparison of Cu
findings to contemporaneous clinical exams obtained with In OctreoScan SPECT or Ga DOTA NOC
PET These Phase experiments are expected to demonstrate that Cu DOTA TATE can be reliably and
robustly compounded at high radiochemical purity and that whole body Cu DOTA TATE PET
appears suitable for clinical neuroendocrine tumor imaging thereby establishing the foundation for
Phase studies to assess the efficacy of Cu DOTA TATE PET CT in patient management Statement of Relevance
This project will advance public health by development of an imaging technology that improves
detection of neuroendocrine tumors as well as physicianandapos s ability to plan appropriate treatment
of patients with neuroendocrine cancer The proposed tumor targeted copper
radiopharmaceutical can be commercially distributed to any clinical PET imaging facility in the
United States relying on a longer lived zinc copper parent daughter radionuclide
generator system already developed by Proportional Technologies Inc thereby providing
universal patient access to receptor based PET neuroendocrine tumor imaging

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government